AMSTERDAM and SAN DIEGO, Jan. 9,
2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a
global leader in health technology, and Illumina,
Inc. (NASDAQ:ILMN), the global leader in DNA sequencing and
array-based technologies, today announced a strategic collaboration
that aims to integrate Illumina's sequencing systems for
large-scale analysis of genetic variation and function and Philips'
IntelliSpace Genomics clinical informatics platform, and to
coordinate marketing and sales of the resulting solutions. Philips
and Illumina will also seek to engage in clinical research
collaborations with health systems in the US that want to develop
precision medicine programs in oncology.
Profiling tumors using genomic information is critical for
complex cancer cases, and next-generation DNA sequencing – the
process of rapidly profiling large sections of the genome in
parallel to find mutations – is increasingly being used for this.
However, challenges remain in developing ways to rapidly and
accurately interpret genomic findings in the context of a patient's
condition. While cancer patients can have hundreds of gene variants
in their tumors, only a small number may actually drive the
individual's specific cancer or may have actionable therapeutic
implications for a particular patient. The patient's history,
related lab tests and cancer type are needed for a meaningful
interpretation of the genomic data.
Philips and Illumina will collaborate to provide new solutions
aimed at the acquisition, analysis, annotation and interpretation
of genomics data in oncology cases. The data will be acquired by
Illumina's BaseSpace® Sequence Hub connected to
its instruments and will be processed through Philips' IntelliSpace
Genomics solution for oncology. This solution will combine data
from multiple sources — radiology, immunohistochemistry, digital
pathology, medical records and lab tests — and will deliver a
consolidated dashboard view. This system will support researchers
to develop insights more efficiently and will ultimately support
lowering the cost of health care delivery and improved health
outcomes.
"The value of genomic information for personalized care, and for
the treatment of patients with cancer in particular, is
tremendous," said Jeroen Tas, CEO of Connected Care and Health
Informatics at Philips. "Until now the ability to use genomic data
with the aim of having a precise diagnosis of cancer and improve
treatment was mostly for the domain of academic centers. Through
this collaboration we will unlock the value of genomics for a much
wider group of laboratories and care providers to help them advance
genomics initiatives at greater speed with the aim to offer
precision medicine with better outcomes for their patients."
"We believe that this collaboration will provide an excellent
path for our next-generation sequencing systems to be incorporated
into health systems in the U.S. and worldwide," said Francis
deSouza, President and CEO of Illumina. "One key strategy in our
commitment to improving human health is connecting genomics to the
everyday business of healthcare: based on integrated patient data,
embedded into clinical pathways, supported by real-world evidence
and reimbursement models."
The two companies intend to collaborate on system integration,
cohort analysis and health economics applications, and future
research programs. Laboratories adopting the solution will be able
to integrate sequencing data with information from multiple data
sources (e.g., imaging, pathology and laboratory). The
Illumina-Philips solution will also give them ready access to
advanced analytics, deep learning technologies and available
reference literature, guidelines, and evidence in a single
view.
IntelliSpace Genomics is powered by Philips HealthSuite, a
secure, cloud-enabled ecosystem of systems, clinical applications
and digital tools that gives access to advanced capabilities such
as universal big data management, predictive analytics, artificial
intelligence and Internet of Things (IoT) to support clinicians in
first-time-right decision support. This enables Philips
IntelliSpace Genomics to deliver real-time, actionable information
to physicians and specialists for therapy planning, across
locations.
BaseSpace® Sequence Hub is a cloud-based platform
that seamlessly extends Illumina instruments for the acquisition
and analysis of genomic data, and managing sequencing runs and
Illumina sequencing platforms to optimize operations. It enables
the sharing of genomic data with a broad range of value-added
Illumina and ecosystem analysis applications.
For Research Use Only. Not for use in diagnostic
procedures.
For further information, please contact:
Steve Klink
Philips Group Communications
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com
Kathy O'Reilly
Philips Group Communications
Tel: +1 978-221-8919
E-mail: Kathy.Oreilly@Philips.com
Twitter: @kathyoreilly
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2015 sales of
EUR 16.8 billion and employs
approximately 70,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter
About Illumina
Illumina is improving human
health by unlocking the power of the genome. Our focus on
innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used
for applications in the life sciences, oncology, reproductive
health, agriculture, and other emerging segments. To learn more,
visit www.illumina.com and follow @illumina.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-and-illumina-join-forces-to-offer-integrated-genomics-solutions-for-oncology-300387605.html
SOURCE Royal Philips